Geron (GERN) AI Stock Analysis

• Market Cap: $848.56M
• Dividend Yield: N/A
• Average Volume (3M): 7.24M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.31
• Revenue Growth: 11877.28%
• EPS Growth: 63.14%
• Country: US
• Employees: 229
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.02
• Shares Outstanding: 638,017,100
• 10 Day Avg. Volume: 7,354,757
• 30 Day Avg. Volume: 7,240,742
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.94
• Enterprise Value/Revenue: 4.86
• Enterprise Value/Gross Profit: 4.96
• Enterprise Value/Ebitda: -12.53
• 1Y Price Target: $3.08
• Price Target Upside: 142.52% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7

• Rating: 49 Neutral
• Price Target: $1.50 ▲(18.11% Upside)

Geron's overall stock score is primarily influenced by its strong revenue growth and strategic initiatives for RYTELO, as highlighted in the earnings call. However, ongoing profitability challenges, weak technical indicators, and a negative valuation score due to losses weigh heavily on the overall assessment.

Positive Factors

Revenue Growth

The significant revenue growth for RYTELO indicates strong market demand and successful commercialization efforts, which can lead to sustained financial performance.

Market Expansion

Expanding the sales force and medical affairs team enhances market penetration and customer engagement, supporting long-term growth and competitive positioning.

Strong Payer Access

High payer access ensures broad patient reach and revenue stability, reinforcing the product's market acceptance and potential for sustained sales growth.

Negative Factors

Profitability Challenges

Ongoing losses and negative profit margins indicate challenges in achieving profitability, which could impact long-term financial health and investment capacity.

Cash Flow Issues

Negative cash flows highlight operational inefficiencies and the need for improved cash management, potentially limiting growth investments and financial flexibility.

European Commercialization Uncertainty

Uncertainty in European market entry could delay revenue diversification and growth opportunities, affecting long-term strategic expansion plans.

Geron Business Overview & Revenue Model

Company Description

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

How the Company Makes Money

Geron generates revenue primarily through collaborations, partnerships, and potential future product sales. The company has engaged in strategic collaborations with larger pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties on product sales. As Geron advances its clinical trials and potentially gains regulatory approval for its drug candidates, it may also start to generate revenue from product sales. Additionally, the company may receive funding through grants and research contracts, especially if its therapies demonstrate significant promise in clinical trials.

Geron Financial Statement Overview

Summary

Geron's financials show significant challenges with profitability, marked by negative net income and EBIT margins. Despite revenue growth, the company faces persistent net losses and negative cash flows, indicating financial strain and sustainability concerns.

Income Statement

Geron's income statement reveals significant challenges with profitability, as highlighted by negative net income and EBIT margins over the periods analyzed. Despite a sharp increase in total revenue in the TTM period, the company still reports significant net losses, affecting its overall profitability. This indicates ongoing financial strain likely due to high operational costs or expenses exceeding revenue gains.

Balance Sheet

The balance sheet indicates moderate financial health with a relatively stable debt-to-equity ratio. The company's equity ratio shows a reasonable proportion of equity financing, though total liabilities have been increasing, reflecting potential leverage concerns. However, the consistent increase in total assets suggests investment and growth potential.

Cash Flow

Geron's cash flow statements highlight negative free cash flow and operating cash flows, indicating cash burn likely due to ongoing investments or operational challenges. Although there are positive financing cash flows, the inability to generate positive operating cash flow is concerning for long-term sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	164.45M	76.99M	237.00K	596.00K	1.39M	253.00K
Gross Profit	161.21M	75.74M	-123.50M	-272.00K	610.00K	-49.80M
EBITDA	-63.78M	-154.85M	-174.78M	-134.15M	-111.59M	-73.92M
Net Income	-88.01M	-174.57M	-184.13M	-141.03M	-120.95M	-75.61M
Balance Sheet
Total Assets	555.20M	594.46M	394.08M	190.57M	226.03M	270.73M
Cash, Cash Equivalents and Short-Term Investments	387.98M	406.57M	333.70M	173.11M	183.72M	196.64M
Total Debt	121.84M	121.72M	85.90M	55.75M	55.00M	29.72M
Total Liabilities	295.67M	313.46M	146.13M	110.58M	99.62M	59.78M
Stockholders Equity	259.53M	280.32M	247.95M	80.00M	126.42M	210.95M
Cash Flow
Free Cash Flow	-178.28M	-219.30M	-168.57M	-127.81M	-95.76M	-67.05M
Operating Cash Flow	-178.28M	-218.62M	-167.74M	-127.38M	-95.56M	-66.65M
Investing Cash Flow	-31.31M	-106.00M	-180.32M	62.07M	71.95M	-105.32M
Financing Cash Flow	171.09M	334.37M	362.02M	87.26M	48.56M	168.35M

Geron Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.27
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GERN, the sentiment is Negative. The current price of 1.27 is below the 20-day moving average (MA) of 1.34, below the 50-day MA of 1.33, and below the 200-day MA of 1.89, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 41.87 is Neutral, neither overbought nor oversold. The STOCH value of 59.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GERN.

Geron Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
QURE	54 Neutral	2.61B	-13.43	3547.93%	―	-48.25%	33.77%
GERN	49 Neutral	$848.56M	―	-31.09%	―	11877.28%	63.14%
SNDX	48 Neutral	1.29B	-3.85	―	―	2133.71%	-15.38%
CRMD	47 Neutral	877.38M	14.89	―	―	14970.29%	―
ANAB	45 Neutral	619.85M	-4.92	296.41%	―	304.17%	29.37%
AVBP	39 Underperform	724.56M	-4.28	―	―	―	-79.41%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Geron Corporate Events

Geron Appoints Harout Semerjian as New CEO

On August 1, 2025, Geron Corporation’s Board of Directors appointed Harout Semerjian as the new President and CEO, effective August 7, 2025, replacing Dawn C. Bir. Mr. Semerjian brings extensive experience from his previous roles in the biotechnology and pharmaceutical sectors, including leadership positions at GlycoMimetics, Immunomedics, and Ipsen Pharma. The appointment is accompanied by an employment agreement that includes a substantial compensation package and stock options, reflecting the company’s strategic focus on strengthening its leadership team. Additionally, the company amended its severance plan and inducement award plan to align with these leadership changes, indicating a commitment to attracting and retaining top talent in the industry.